All data are based on the daily closing price as of July 18, 2024
h

Hanall Biopharma

009420.KO
26.04 USD
-0.52
-1.96%

Overview

Last close
26.04 usd
Market cap
1.32B usd
52 week high
34.35 usd
52 week low
11.72 usd
Target price
33.38 usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
12.8516
Price/Book Value
9.3106
Enterprise Value
1.31B usd
EV/Revenue
12.4424
EV/EBITDA
257.7173

Key financials

Revenue TTM
101.41M usd
Gross Profit TTM
44.75M usd
EBITDA TTM
4.95M usd
Earnings per Share
N/A usd
Dividend
N/A usd
Total assets
164.53M usd
Net debt
N/A usd

About

Hanall Biopharma Co., Ltd., a pharmaceutical company, manufactures and sells pharmaceutical products in South Korea and internationally. The company offers prescription drugs and over-the-counter products for the treatment of diarrhea, prostatic hyperplasia, androgenetic alopecia, chronic renal failure, hypoparathyroidism, vitamin D-resistant rickets, osteomalacia, osteoporosis, prostate cancer, toxic liver disease, chronic hepatitis, liver cirrhosis, male pattern baldness, functional dyspepsia, diabetes, bacterial infections, peripheral vascular disorders, hypertension, chronic heart failure, skin diseases, hypoproteinemia, diabetic polyneuritis, ulcers, high blood pressure, arthritis, endocrine disorders, spasms, insomnia, muscle pain, hypoproteinemia, gastroesophageal reflux disease, allergic rhinitis, conjunctivitis, dermatitis, chronic urticaria, cholesterol cholelithiasis, gastritis, neurological diseases, erectile dysfunction, hyperphosphatemia, urinary tract infection, spastic paralysis, fungal infections, dysmenorrhea, hypercholesterolemia, constipation, abdominal distension, abdominal fermentation in the intestines, neuralgia, capillary weakness, post-phlebitis syndrome, irritable bowel syndrome, spastic colon, and hemorrhoids, as well as vitamin D, vitamin B1, vitamin B12, and calcium deficiency. It develops products in the fields of ophthalmology, immunology, oncology, and neurology, such as HL192 for Parkinson's disease; HL036 for dry eye disease; HL161 for myasthenia gravis, thyroid eye disease, warm autoimmune hemolytic anemia, neuromyelitis optica, immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy, and graves' disease; and HL187 and HL186 for immuno-oncology. The company was founded in 1973 and is headquartered in Daejeon, South Korea.
  • Symbol
    009420.KO
  • Exchange
    KO
  • Isin
    KR7009420001
  • Country
    South Korea
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - Specialty & Generic
  • CEO
    Sean Jeong
  • Headquarter
    Daejeon
  • Web site
    https://www.hanall.co.kr
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top